Therapeutic cancer vaccines and combination immunotherapies involving vaccination

Recent US Food and Drug Administration approvals of Provenge(®) (sipuleucel-T) as the first cell-based cancer therapeutic factor and ipilimumab (Yervoy(®)/anticytotoxic T-lymphocyte antigen-4) as the first “checkpoint blocker” highlight recent advances in cancer immunotherapy. Positive results of th...

Descripción completa

Detalles Bibliográficos
Autores principales: Nguyen, Trang, Urban, Julie, Kalinski, Pawel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4918241/
https://www.ncbi.nlm.nih.gov/pubmed/27471705
http://dx.doi.org/10.2147/ITT.S40264

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4918241/
https://www.ncbi.nlm.nih.gov/pubmed/27471705
http://dx.doi.org/10.2147/ITT.S40264

Ejemplares similares